Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology director Theagene Jean-Manasse received a grant of stock options for
Cristian Luput, a director of MAIA Biotechnology, Inc. (MAIA), reported a grant of stock options on
The Form 4 was signed on
MAIA Biotechnology, Inc. director Louie Ngar Yee reported a grant of 25,331 stock options on
MAIA Biotechnology, Inc. director Ramiro Guerrero was granted 20,459 stock options on
MAIA Biotechnology director Steven M. Chaouki received a grant of 20,946 stock options under the 2021 Equity Incentive Plan. The options are exercisable immediately, vesting 100% on grant, and carry an exercise price of
This action increases the director's potential economic exposure to the company’s common stock and creates a near-term option position that could be exercised to acquire shares at the stated exercise price.
Stan V. Smith, a director of MAIA Biotechnology, Inc. (MAIA), purchased 19,230 shares of common stock on 10/01/2025 at a price of $1.30 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. The transaction increased beneficial ownership to 1,324,289 shares, held indirectly through The Stan V. Smith Trust Dated 1993. In the same transaction Mr. Smith acquired 19,230 warrants (treated as options) with a $1.57 exercise price; those options become exercisable six months after issuance and expire three years after issuance (exercise window: 04/01/2026 through 10/01/2028). The Form 4 was signed on 10/02/2025.
MAIA Biotechnology reported a material financing-related disclosure. The Board approved director participation in a Private Placement to align director and stockholder interests. A director, Stan Smith, executed a Purchase Agreement to subscribe for 19,230 shares of common stock at $1.30 per share for an aggregate of approximately $25,000 and received warrants to purchase up to 19,230 shares exercisable at $1.57 beginning six months after issuance with a three-year term. The Director Shares and Director Warrants are being issued under the Company’s 2021 Equity Incentive Plan as an Unrestricted Stock Award and an Award of Options. Separately, the company amended certain common stock purchase warrants originally issued February 24, 2025 to reduce the exercise price from $1.87 to $1.30 for warrants to purchase 1,396,667 shares, including amendments affecting FGMK Holdings LLC for warrants to purchase 1,350,000 shares. Several related forms and a press release are filed as exhibits.
MAIA Biotechnology announced that it has been awarded a $2.3 million grant from the National Institutes of Health. The funding is designated to expand its THIO-101 Phase 2 clinical trial, which is evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung cancer. This grant supports further clinical development of the program without relying on equity financing. The company provided more details in a press release attached as an exhibit.
MAIA Biotechnology, Inc. entered into inducement letter agreements with several accredited investors holding existing warrants to buy its common stock. These investors agreed to exercise warrants for a total of 440,503 shares of common stock (the “Exercise Shares”) at a reduced cash exercise price of $1.30 per share. In return, MAIA expects to receive approximately $572,654 in gross proceeds before expenses.
The Exercise Shares will be issued as restricted securities on or about the stated closing date and will not be registered under the Securities Act, bearing a restrictive legend. MAIA states that it intends to use the net proceeds from these warrant exercises for general corporate purposes. The company relies on exemptions from registration, including Section 4(a)(2), Rule 506 and/or Section 3(a)(9) of the Securities Act, for this private issuance.
MAIA Biotechnology, Inc. filed a current report to note that it has posted an updated presentation about its business on its website. The slide deck, filed as Exhibit 99.1 and incorporated by reference, is intended to provide summary information alongside the company’s other SEC filings and public announcements. The company states that the presentation speaks only as of the report date and that it does not undertake an obligation to update it. The materials contain forward-looking statements, and investors are cautioned not to place undue reliance on those statements.